Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology firm known for its innovative approaches to tackling protein dysregulation, has announced its participation in the Cantor Fitzgerald Global Healthcare Conference. Scheduled for Thursday, September 4, 2025, at 10:55 a.m. ET in New York City, the event will feature a fireside chat with senior members of Prothena's management team. Interested parties can access a live webcast of the discussion via the investor relations section of the company's website, www.prothena.com. Following the live event, a replay of the broadcast will be available for viewing for 90 days.

Prothena's expertise lies in developing investigational therapeutics aimed at treating various neurodegenerative and rare peripheral amyloid diseases. The company's robust pipeline, built on decades of scientific research, showcases its commitment to finding treatments for conditions such as ATTR amyloidosis, Alzheimer’s disease, and Parkinson’s disease. By integrating insightful scientific knowledge regarding neurological dysfunction and the biology of misfolded proteins, Prothena is poised to bring important advancements in therapeutic candidates targeting these challenging diseases.

As a player in the biotech sector, Prothena continues to focus on pushing the boundaries of innovation in medicine, offering hope for those affected by debilitating disorders. Stakeholders and interested investors are encouraged to view the upcoming fireside chat to gain insights into Prothena’s current projects and strategic direction.

For further details, investors can contact Mark Johnson, CFA, Vice President of Investor Relations, at 650-837-8550 or via email at IR@prothena.com. Additionally, the company maintains an active presence on X (formerly Twitter) under the handle @ProthenaCorp, where further updates and information can be found.

Prothena Corporation plc (NASDAQ:PRTA) is positioning itself for potential growth as it prepares to participate in the Cantor Fitzgerald Global Healthcare Conference on September 4, 2025. The spotlight on Prothena's management team during this high-profile event will likely provide a valuable opportunity for investors to gain insights into the company's trajectory, particularly regarding its promising therapeutic pipeline focused on tackling debilitating neurodegenerative and amyloid diseases.

As a late-stage clinical biotechnology company, Prothena has demonstrated considerable expertise in addressing protein dysregulation, a critical factor in various diseases, including ATTR amyloidosis, Alzheimer’s, and Parkinson’s. The upcoming fireside chat could reveal strategic developments and updates on clinical trials that could affect both market perception and stock performance.

Investors should pay attention to the key messages from this presentation, especially insights related to the timelines of ongoing clinical trials and potential partnerships that could enhance the company’s research capabilities. Given the increasing focus on neurodegenerative conditions and the growing demand for innovative treatments, Prothena's ability to deliver on its pipeline could position it favorably within the biotechnology sector.

It’s also vital to monitor market sentiment leading up to and following the conference. Should the management team provide positive updates, it could bolster investor confidence and create upward momentum for Prothena’s stock. Conversely, any uncertainties or delays could lead to volatility.

For those considering an investment in Prothena, this conference serves as a pivotal moment to assess the company’s current standing and future prospects. Investors should utilize the webcast available on Prothena's investor relations page to gather insights directly from the company, thereby informing their investment decisions going forward.